Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a research-stage biotech can be harder to navigate than the science itself. bioAffinity Technologies Inc., developer of the CyPath Lung non-invasive test, fills each report with flow-cytometry data, clinical protocols, and licensing notes. Finding trial milestones, R&D burn, or insider sentiment quickly is a real challenge—exactly the problem Stock Titan solves with bioAffinity Technologies SEC filings explained simply.
Our AI engine parses every submission from EDGAR in seconds, tags it by topic, and delivers the context you need:
- bioAffinity Technologies insider trading Form 4 transactions in minutes
- bioAffinity Technologies quarterly earnings report 10-Q filing distilled
- bioAffinity Technologies 8-K material events explained
- bioAffinity Technologies annual report 10-K simplified
- bioAffinity Technologies proxy statement executive compensation clearly shown
- bioAffinity Technologies Form 4 insider transactions real-time alerts
- bioAffinity Technologies earnings report filing analysis with trend charts
- understanding bioAffinity Technologies SEC documents with AI made easy
- bioAffinity Technologies executive stock transactions Form 4 mapped to announcements
Whether you’re monitoring insider buys before a clinical update, comparing quarter-over-quarter cash burn, or assessing how licensing revenue offsets trial costs, our platform keeps you informed. Real-time alerts, AI-written highlights, and original documents sit side by side, letting investors and healthcare analysts move from raw data to decisions in seconds—no more hunting through footnotes.
bioAffinity Technologies, Inc. (BIAFW) reported interim results showing continued operating losses and tight liquidity. For the periods presented the company recorded operating losses of $2,515,560 and $5,142,699 (three and six months) and net loss before income tax expense of $4,031,803 and $6,683,525. Total net revenue was $1,269,483 and $3,123,080 for the three and six month periods presented. Cash and cash equivalents at June 30, 2025 were approximately $0.8 million. In May 2025 the company completed a public offering raising $3.25 million gross proceeds and recorded warrant remeasurement losses of roughly $1.0–1.1 million. Management discloses substantial doubt about the company’s ability to continue as a going concern beyond twelve months and states existing cash is sufficient only through August 2025 without additional financing. The filing describes material potential dilution from outstanding warrants and recent fundraising and notes Nasdaq non-compliance issues and subsequent appeal.
bioAffinity Technologies, Inc. disclosed that Nasdaq notified the company it failed to maintain the $1.00 minimum bid price for the period December 23, 2024 through February 6, 2025 and did not regain compliance by the 180-day cure deadline. The Listing Qualifications Staff also determined the company is ineligible for a second compliance period because its reported stockholders' equity of $1,439,404 as of March 31, 2025 is below Nasdaq's $2,500,000 minimum for continued listing.
The company was told its securities will be scheduled for delisting and suspended at the opening of business on August 18, 2025 unless it requests an appeal by August 14, 2025. bioAffinity intends to file an appeal to stay the suspension and will present its plan to regain compliance; hearings are typically scheduled ~30-45 days after a hearing request and the Panel typically issues a decision within ~30 days after the hearing. The filing also notes a press release announcing increased commercial sales of CyPath® Lung.
FAQ
What is the current stock price of bioAffinity Tech (BIAFW)?
